公开(公告)号：US20170023586A1

公开(公告)日：2017-01-26

申请号：US15189062

申请日：2016-06-22

Applicant: Immport Therapeutics, Inc.

Inventor： Philip Felgner ,  Xiaowu Liang ,  Maria Laura Gennaro

IPC: G01N33/68

CPC classification number: C12N15/1068 ,  A61K39/015 ,  A61K39/0208 ,  A61K39/0225 ,  A61K39/04 ,  A61K39/098 ,  A61K39/118 ,  A61K39/12 ,  A61K39/245 ,  A61K39/285 ,  A61K39/385 ,  A61K2039/60 ,  C07K14/005 ,  C12N2710/16621 ,  C12N2710/16622 ,  C12N2710/16634 ,  C12N2710/24122 ,  C12N2710/24134 ,  G01N33/566 ,  G01N33/56911 ,  G01N33/56916 ,  G01N33/56927 ,  G01N33/5695 ,  G01N33/56983 ,  G01N33/56994 ,  G01N33/6854 ,  G01N2333/35 ,  G01N2469/20 ,  Y02A50/401 ,  Y02A50/412

Abstract: Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen M. tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter

Abstract translation: 研究的组合物，装置和方法被描绘为来自病原体结核分枝杆菌的各种抗原及其在疫苗，治疗剂和各种诊断测试中的用途。 在特别优选的方面，抗原是免疫显性的，并且相对于感染病原体的群体的血清具有定量和已知的相对反应性，和/或具有与疾病参数的已知关联

公开(公告)号：US09512186B2

公开(公告)日：2016-12-06

申请号：US14379149

申请日：2013-02-18

Applicant: FUNDACAO BUTANTAN

Inventor： Luciana Cezar De Cerqueira Leite ,  Ivan Pereira Nascimento

IPC: A61K39/04 ,  A61K49/00 ,  A61K39/02 ,  C07K14/245 ,  A61K39/00

CPC classification number: C07K14/245 ,  A61K39/04 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/545 ,  A61K2039/55516

Abstract: The present invention relates to recombinant Mycobacterium strain that encodes the mutated Escherichia coli LT heat-labile toxin or the A subunit of the mutated Escherichia coli LT heat-labile toxin. The present invention also relates to strains of Mycobacterium that encode the LT heat-labile toxin or the A subunit of the LT heat-labile toxin of Escherichia coli mutated in position 63. Specifically, the present invention relates to strains of Mycobacterium that encode the LT heat-labile toxin or the A subunit of the LT heat-labile toxin of Escherichia coli mutated in position 63 from serine to lysine. The present invention also provides immunogenic compositions that comprise the strains of the present invention. The present invention further provides for the use of said strains and immunological compositions in the production of a vaccine for preventing tuberculosis and infections caused by Mycobacterium tuberculosis. Lastly, the present invention relates to methods for preventing or treating tuberculosis in animals.

Abstract translation: 本发明涉及编码突变的大肠杆菌LT热不稳定毒素或突变的大肠杆菌LT热不稳定毒素的A亚基的重组分枝杆菌菌株。 本发明还涉及编码LT耐热毒素或在63位突变的大肠杆菌的LT热不稳定毒素的A亚基的分枝杆菌菌株。具体地，本发明涉及编码LT的分枝杆菌菌株 热不稳定毒素或大肠杆菌LT热不稳定毒素的A亚基在63位从丝氨酸突变至赖氨酸。 本发明还提供包含本发明菌株的免疫原性组合物。 本发明进一步提供所述菌株和免疫组合物在制备用于预防由结核分枝杆菌引起的结核病和感染的疫苗中的用途。 最后，本发明涉及用于预防或治疗动物结核病的方法。

公开(公告)号：US09463239B2

公开(公告)日：2016-10-11

申请号：US14048757

申请日：2013-10-08

Applicant: GEORGIA REGENTS RESEARCH INSTITUTE, INC.

Inventor： David Munn ,  Andrew Mellor

IPC: A61K31/405 ,  A61K39/39 ,  A61K31/343 ,  A61K31/381 ,  A61K31/704 ,  A61K39/00 ,  A61K39/002 ,  A61K39/02 ,  A61K39/04 ,  A61K39/21 ,  A61K39/245 ,  C12N7/00

CPC classification number: A61K39/39 ,  A61K31/343 ,  A61K31/381 ,  A61K31/405 ,  A61K31/704 ,  A61K39/0011 ,  A61K39/002 ,  A61K39/0208 ,  A61K39/04 ,  A61K39/21 ,  A61K39/245 ,  A61K2039/55511 ,  C12N7/00 ,  C12N2710/16134 ,  C12N2710/16171 ,  C12N2740/16034 ,  C12N2740/16071 ,  Y02A50/409 ,  Y02A50/411

Abstract: The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.

公开(公告)号：US09415078B2

公开(公告)日：2016-08-16

申请号：US14628534

申请日：2015-02-23

Applicant: Cadila Pharmaceuticals, Ltd.

Inventor： Bakulesh Mafatlal Khamar ,  Indravadan Ambalal Modi

IPC: A61K35/74 ,  A61K45/06 ,  C12N1/20 ,  A61K39/04 ,  A61K39/00

CPC classification number: A61K35/74 ,  A61K39/04 ,  A61K45/06 ,  A61K2039/521 ,  A61K2039/585 ,  C12N1/20

Abstract: The present invention relates to increase in survival of mammals suffering from desmocollin 3 expressing cancers. Mycobacterium w is administered to mammals suffering from desmocollin-3 expressing cancers. The administration of Mycobacterium w results in control of tumor and improvement in survival. Mycobacterium w can also be used along with other therapeutic agent(s)/modalities as per the requirement. The squamous type of non small cell lung cancer is known to be desmocollin-3 expressing cancer. Other cancers also express desmocollin-3.

Abstract translation: 本发明涉及具有表达癌细胞蛋白3的哺乳动物的存活率的增加。 将分枝杆菌施用于患有表达肌球蛋白-3的癌症的哺乳动物。 分枝杆菌的施用导致肿瘤的控制和存活的改善。 分枝杆菌w也可以与其他治疗剂/模式一起使用。 已知鳞状淋巴细胞型非小细胞肺癌是表达desmocollin-3的癌症。 其他癌症也表达去屑球蛋白-3。

公开(公告)号：US20160195529A1

公开(公告)日：2016-07-07

申请号：US14916632

申请日：2014-09-04

Applicant: IMPERIAL INNOVATIONS LIMITED

Inventor： Ajit Lalvani ,  Katrina Mary Pollock ,  Graham Taylor ,  Hilary Sian Whitworth

IPC: G01N33/569

CPC classification number: G01N33/56966 ,  A61K39/04 ,  G01N33/505 ,  G01N33/5695 ,  G01N2333/35 ,  G01N2333/525 ,  G01N2333/57 ,  G01N2333/70514 ,  G01N2333/70517 ,  G01N2333/70589 ,  G01N2800/26 ,  G01N2800/56

Abstract: There is provided methods of determining tuberculosis (TB) infection status in an individual comprising: (i) providing a sample comprising T-cells; (ii) exposing the sample of (i) to one or more TB antigens; (iii) identifying T-cells in the sample that are CD4 positive and (a) secrete TNF-α without secreting IFN-γ; or (b) secrete IFN-γ without secreting TNF-α; (iv) identifying those cells of (iii) which are also CCR7 and, CD127 negative; and optionally (v) calculating the cells identified in (iv) as a percentage of those identified in (iii); wherein the identification of cells in (iv) and/or the percentage of T-cells calculated in (v) correlates to TB infection status of the individual, and wherein steps (iii) and (iv) can be carried out either sequentially or simultaneously. There are also provided compositions and kits for use in such methods.

Abstract translation: 提供了确定个体中结核病（TB）感染状态的方法，包括：（i）提供包含T细胞的样品; （ii）将（i）的样品暴露于一种或多种TB抗原; （iii）鉴定CD4阳性样本中的T细胞，（a）分泌TNF-α而不分泌IFN-γ; 或（b）分泌IFN-γ而不分泌TNF-α; （iv）鉴定也是CCR7的那些（iii）细胞，CD127是阴性的; 和（v）计算在（iv）中鉴定的细胞占在（iii）中鉴定的细胞的百分比; 其中在（iv）中计算的（iv）中的细胞和/或T细胞的百分比的鉴定与个体的TB感染状态相关，并且其中步骤（iii）和（iv）可以顺序地或同时进行 。 还提供了用于这些方法的组合物和试剂盒。

公开(公告)号：US09376686B2

公开(公告)日：2016-06-28

申请号：US13624146

申请日：2012-09-21

Applicant: Antonio Campos-Neto ,  Mark Cayabyab ,  Margaret Duncan

Inventor： Antonio Campos-Neto ,  Mark Cayabyab ,  Margaret Duncan

IPC: A61K39/09 ,  A61K39/21 ,  A01N63/00 ,  C12P21/04 ,  C12N15/74 ,  C07K14/00 ,  C07K14/155 ,  C07K14/16 ,  C07K14/35 ,  C07K14/005 ,  C07K14/315

CPC classification number: A61K39/21 ,  A61K39/04 ,  A61K45/06 ,  A61K2039/523 ,  A61K2039/542 ,  A61K2039/572 ,  C07K14/00 ,  C07K14/005 ,  C07K14/155 ,  C07K14/162 ,  C07K14/315 ,  C07K14/35 ,  C07K2319/02 ,  C07K2319/40 ,  C12N7/00 ,  C12N9/2457 ,  C12N15/74 ,  C12N15/746 ,  C12N2740/15022 ,  C12N2740/15033 ,  C12N2740/16022 ,  C12N2740/16033 ,  C12N2740/16034 ,  C12N2740/16051 ,  C12N2740/16071 ,  C12N2740/16111 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12Y302/01041

Abstract: The present invention relates to a new vaccine delivery system. In particular, the present invention includes compositions and methods of integrally transformed non-pathogenic, commensal bacteria that can express a nucleic acid molecule of a foreign polypeptide, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacteria. The foreign polypeptide includes a vaccine antigen that elicits an immunogenic response, an inhibitor of a pathogen, or an immune booster or modulator.

Abstract translation: 本发明涉及新的疫苗递送系统。 特别地，本发明包括能够表达外来多肽的核酸分子的整合转化的非致病性共生细菌的组合物和方法，其中编码外来多肽的核酸分子稳定整合到细菌的基因组DNA中 。 外来多肽包括引起免疫原性应答的疫苗抗原，病原体抑制剂或免疫增强剂或调节剂。

公开(公告)号：US20160153987A1

公开(公告)日：2016-06-02

申请号：US15016859

申请日：2016-02-05

Applicant: The Secretary of State for Environment, Food and Rural Affairs

Inventor： Hans Martin Vordermeier ,  Benjamin Sidders ,  Neil Graham Stoker ,  Katie Ewer

IPC: G01N33/569 ,  C07K7/08 ,  C07K14/35

CPC classification number: G01N33/5695 ,  A61K39/00 ,  A61K39/02 ,  A61K39/04 ,  C07K7/08 ,  C07K14/35 ,  G01N2333/35

Abstract: There is provided a diagnostic reagent for use in the detection of M. bovis or M. tuberculosis infection in an animal, comprising a peptide which has an epitope from Mycobacterium bovis hypothetic protein Mb3645c (SEQ ID NO: 1) or an epitope from a polypeptide having at least 76% identity with SEQ ID NO: 1.

Abstract translation: 提供了一种用于检测动物中牛分枝杆菌或结核分枝杆菌感染的诊断试剂，其包含具有牛分枝杆菌假单胞蛋白Mb3645c（SEQ ID NO：1）或来自多肽的表位的表位的肽 与SEQ ID NO：1具有至少76％的同一性。

公开(公告)号：US09345756B2

公开(公告)日：2016-05-24

申请号：US14385606

申请日：2013-02-19

Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE

Inventor： Ryuichi Sakamoto ,  Masashi Sakaguchi

IPC: A61K39/02 ,  A61K39/295 ,  A61K39/215 ,  A61K39/235 ,  A61K39/112 ,  A61K39/102 ,  A61K39/00 ,  A61K39/17

CPC classification number: A61K39/0275 ,  A61K39/0208 ,  A61K39/0241 ,  A61K39/025 ,  A61K39/04 ,  A61K39/102 ,  A61K39/17 ,  A61K39/215 ,  A61K39/235 ,  A61K39/295 ,  A61K2039/552 ,  A61K2039/6037 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/10234 ,  C12N2710/10271 ,  C12N2770/20034 ,  C12N2770/20071 ,  Y02A50/482

Abstract: A vaccine composition for birds comprising as an active ingredient a structure containing O-antigen derived from Gram-negative bacteria, provided that said structure does not contain a whole cell, and a process for preparing the same are provided. By using a structure containing O-antigen (e.g. lipopolysaccharide) derived from Gram-negative bacteria as an active ingredient in accordance with the present invention, alleviation of inoculation reaction and reduction in an amount of injection are attained as compared to the conventional whole-cells vaccine to thereby allow for the increase in the number of other antigens to be mixed therewith.

Abstract translation: 一种用于鸟类的疫苗组合物，其包含作为活性成分的含有衍生自革兰氏阴性细菌的O-抗原的结构，条件是所述结构不包含全细胞，并提供其制备方法。 通过使用根据本发明的衍生自革兰氏阴性细菌的O-抗原（例如脂多糖）的结构作为活性成分，与常规全细胞相比，获得了接种反应的减轻和注射量的减少 疫苗，从而允许增加与其混合的其它抗原的数量。

公开(公告)号：US20160103127A1

公开(公告)日：2016-04-14

申请号：US14856352

申请日：2015-09-16

Applicant: OREGON HEALTH & SCIENCE UNIVERSITY ,  THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

Inventor： David M. Lewinsohn ,  Deborah A. Lewinsohn

IPC: G01N33/569 ,  A61K9/00 ,  A61K49/00

CPC classification number: A61K39/04 ,  A61K9/0021 ,  A61K38/00 ,  A61K39/385 ,  A61K49/00 ,  A61K49/0006 ,  A61K2039/53 ,  G01N33/5695 ,  G01N2333/35 ,  G01N2469/10 ,  G01N2800/26 ,  Y02A50/466

Abstract: Methods for detecting an infection with Mtb in a subject are disclosed. The methods include detecting the presence of CD8+ T cells that specifically recognize an Mtb polypeptide. The methods include in vitro assays for detecting the presence of CD8+ T cells in a biological sample, and in vivo assays that detect a delayed type hypersensitivity reaction. The methods also include detecting Mtb polypeptides and polynucleotides.

Abstract translation: 公开了用于检测受试者中Mtb感染的方法。 所述方法包括检测特异性识别Mtb多肽的CD8 + T细胞的存在。 所述方法包括用于检测生物样品中CD8 + T细胞的存在的体外测定法和检测延迟型超敏反应的体内测定。 所述方法还包括检测Mtb多肽和多核苷酸。

公开(公告)号：US20160045591A1

公开(公告)日：2016-02-18

申请号：US14604215

申请日：2015-01-23

Applicant: The Forsyth Institute

Inventor： Antonio Campos-Neto ,  Mark Cayabyab ,  Margaret Duncan

IPC: A61K39/21 ,  A61K39/04 ,  A61K45/06 ,  C07K14/33 ,  C07K14/35 ,  C07K14/005 ,  A61K39/08 ,  C12N7/00

CPC classification number: A61K39/21 ,  A61K39/04 ,  A61K39/08 ,  A61K39/12 ,  A61K45/06 ,  A61K2039/523 ,  A61K2039/541 ,  A61K2039/545 ,  A61K2039/58 ,  C07K14/005 ,  C07K14/315 ,  C07K14/33 ,  C07K14/35 ,  C07K2319/02 ,  C07K2319/21 ,  C07K2319/40 ,  C07K2319/55 ,  C12N9/2402 ,  C12N2740/15022 ,  C12N2740/15033 ,  C12N2740/16033 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171

Abstract: The present invention relates to a new vaccine delivery system. In particular, the present invention includes compositions and methods of integrally transformed non-pathogenic, commensal bacteria that can express a nucleic acid molecule of a foreign polypeptide, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacteria. The foreign polypeptide includes a vaccine antigen that elicits an immunogenic response, an inhibitor of a pathogen, or an immune booster or modulator.

Abstract translation: 本发明涉及新的疫苗递送系统。 特别地，本发明包括能够表达外来多肽的核酸分子的整合转化的非致病性共生细菌的组合物和方法，其中编码外来多肽的核酸分子稳定整合到细菌的基因组DNA中 。 外来多肽包括引起免疫原性应答的疫苗抗原，病原体抑制剂或免疫增强剂或调节剂。